Pheast Therapeutics pockets $76m Series A

Pheast Therapeutics, a developer of novel checkpoint therapies to fight cancer, has raised $76 million in Series A funding.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this